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1.The thesis explained 
 
This study aims to evaluate the effects of the stimulation of the 
AVP-dependent pathways on muscular atrophy.  
Arg-vasopressin (AVP) has been demonstrated to have a potent 
effect as myogenic promoting factor both in vitro and in vivo. In 
skeletal muscle AVP signaling is mediated by the V1a receptor, 
whose stimulation results in the activation of PLC and PLD, 
increased cytosolic calcium concentration and stimulation of CaMK 
(Ca
2+
/calmodulin-dependent protein kinase) and calcineurin 
pathways, leading to the formation of multifactor complexes on the 
promoter of muscle specific genes, thus activating their 
transcription. 
In this study we induced muscular atrophy by local over-expression 
of TNF and we evaluated the effects of the stimulation of AVP 
signaling pathways in this condition by over-expressing V1a 
receptor. TNF is a pro-inflammatory cytokine and it is known to 
inhibit myogenic differentiation both in vitro and in vivo, and we 
have previously demonstrated that the negative effects of TNF in 
vitro is counteracted by AVP treatment. Moreover it has been 
demonstrated that TNF plays a key role in the activation of the 
inflammatory pathways mediated by NF-kB and in the stimulation 
of protein catabolism. For these reasons, we evaluated, in TNF-
expressing muscle, the effects of V1aR over-expression in the 
regeneration process, in the inflammatory status and in protein 
degradation. Morphological and morphometric analysis 
demonstrated that the local over-expression of V1aR in the atrophic 
muscle enhances the cross-sectional area of the regenerating fibers. 
Since we noted the presence of infiltrating mono-nucleated cells in 
muscles over-expressing TNF, we investigated the nature of the 
infiltrate: it is positive for esterase activity, demonstrating the 
presence of macrophages. Esterase activity is reduced in muscles 
over-expressing both TNF and V1aR. We further demonstrated that 
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the up-regulation of NF-kB expression by TNF is reduced by the 
contemporary over-expression of V1aR. We noted a prevalence of 
chemokines and cytokines specific of the pro-inflammatory 
phenotype of macrophages (M1) in the presence of TNF, but an 
increased levels of antigens and anti-inflammatory cytokines 
specific for M2 macrophage phenotype in muscle over-expressing 
both TNF and V1aR. In regards to the regenerative process, the 
expression levels of early regeneration markers, such as Pax7 and 
desmin, are up-regulated by TNF, whereas late differentiation 
markers, such as myogenin and MHC, are down-regulated. The 
simultaneous over-expression of V1aR up-regulates the expression 
of both early and late differentiation markers. These data 
demonstrate that the stimulation of AVP-dependent pathways 
enhances skeletal muscle regeneration. We also analyzed PI3K/Akt 
pathway because TNF is known to induce protein degradation. V1 
over-expression maintains the phosphorylation levels of Akt and 
FoxO, at least inhibiting atrogin-1 transcription activated by TNF, 
thus counteracting protein degradation.  
According to these results we are extending our studies to the 
effects of AVP signaling in muscular dystrophies. Very preliminary 
data suggest a positive role of AVP even in dystrophic muscles in 
mdx and Scgβ-null mice, though technical issues have yet to be 
solved. 
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2. Introduction 
 
2.1. Skeletal muscle homeostasis  
 
The capacity of a biological system to maintain the balance of its 
chemical and physical features, in response to the external stimuli, 
is fundamental for its own function and survival.  
Skeletal muscle tissue represents 40% of the entire body mass and 
is crucial for movement, posture maintenance and equilibrium, 
breathing, heat production, carbohydrates and amino acid storage 
(Kharraz et al., 2013). Skeletal muscle is a dynamic tissue, capable 
to respond to physiological stimuli and to altered homeostatic 
conditions, such as atrophy, or severe injuries by activating a 
regeneration program.  
Skeletal muscle regeneration is an evolutionary preserved, multi-
step process (Kharraz et al., 2013). The starting event is myofiber 
necrosis, in which the partial or total sarcolemmal disruption, with a 
consequent increase in cytosolic calcium (Ca
2+
) concentration, 
induces calpain-mediated proteolysis. Moreover the release in the 
extracellular environment of soluble molecules, such as cytokines 
and chemokines, recruits the circulating inflammatory cells, giving 
rise to a key event of the regeneration (Charge and Rudnicki, 2004). 
Cell populations that infiltrate the damaged area are neutrophils 
(from 1 to 6 hours after damage) followed by macrophages (48 
hours after damage). Neutrophils release reactive oxygen species 
(ROS) and proteases, facilitate phagocytosis and recruit the 
circulating monocytes. Macrophages are responsible not only for 
debris removal but also for the secretion of active molecules 
(cytokines, chemokines and growth factors) that directly influence 
regeneration (Kharraz et al., 2013; Saclier et al., 2013b; Saclier et 
al., 2013a).  
Macrophages are currently divided in two different phenotypes. M1 
macrophages are the first to appear in the damaged area. The M1 
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macrophages sustain inflammation releasing pro-inflammatory 
chemokines and cytokines, such as CCL2, IL1β and IL6. M2 
macrophages are detected later during skeletal muscle regeneration 
and are characterized by the expression of CD163 receptor and by 
the release of anti-inflammatory cytokines, such as IL10 and IL4, 
finally leading to the resolution of inflammation and to tissue repair 
(Kharraz et al., 2013). Skeletal muscle regeneration is stimulated by 
inflammation and it primarily relies on the activation of many stem 
cell population. The resident pool of stem cell is represented by 
satellite cells, quiescent cells located under the basal lamina, 
expressing Pax7 and capable of self-renewal. In addition many 
other cell types contribute to skeletal muscle regeneration, although 
at a lower rate: PW1
+
 interstitial cells (PICs), mesoangioblasts, fibro 
adipogenic cells (FAPs) and, to a lesser extent, also bone marrow 
derived stem cells (Kharraz et al., 2013; Wang and Rudnicki, 2012). 
Satellite cells activation is dependent on soluble factors released by 
the damaged fibers such as FGF (Fibroblast Growth Factor), TGF-β 
(Transforming Growth Factor), HGF (Hepatocyte Growth Factor) 
and nitric oxide (NO) (Chargé and Rudnicki, 2004). The production 
of inflammatory cytokines is fundamental to skeletal muscle 
regeneration. For example, IL-6 induces both the myogenic 
differentiation program via p38 (Wang and Rudnicki, 2012) and the 
proliferation of satellite cells via JAK2-STAT3 (Janus kinase/signal 
transducer and activator of transcription ) (Schiaffino et al., 2013). 
IL-4, highly produced by M2 macrophages, activates myoblast 
fusion leading to the formation of mature myotubes (Schiaffino et 
al., 2013). 
Satellite cells activation implies transcription of MyoD and Myf5 
and then of myogenin and MRF4, a family of bHLH (basic helix-
loop-helix) transcriptional factors of proteins, also called MRFs 
(Myogenic Regulatory Factors) (Yusuf and Brand-Saberi, 2012). 
These transcription factors co-operate with several cofactors 
binding the promoters of muscle specific genes, such as muscle 
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creatin kinase (MCK) and myosin heavy chain (MHC) (Lluìs et al., 
2006). Finally differentiation of the myogenic cells and their fusion 
to form mature myotubes lead to new myofiber formation and to 
tissue repair. At the end of this process the regenerating areas are 
structurally and functionally identical to  the healthy tissue (Chargé 
and Rudnicki, 2004). 
 
 
Another important feature during skeletal muscle repair is 
represented by extracellular matrix (ECM), secreted around every 
single myofiber by resident fibroblasts. The correct amount and the 
Figure 1. Inflammation and macrophage polarization in 
skeletal muscle injury and repair. (Kharraz et al., 2013). 
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spatial distribution of the ECM play a fundamental role as scaffold 
for new myofiber formation (Kharraz et al., 2013; Mann et al., 
2011; Murphy et al., 2012; Serrano et al., 2011). A sustained, 
persistent inflammation as well as an exhaustion of satellite cells 
pool, due to extensive injury (more than 20% of the muscle), ageing 
or altered homeostatic conditions, such as atrophy or dystrophies, 
lead to fibrotic tissue formation and adipose tissue infiltration, 
interfering with the correct repair of skeletal muscle (Carosio et al., 
2011).   
 
 
2.2. Altered homeostatic conditions: hypertrophy and atrophy  
 
Alteration of the homeostatic conditions leads to both hypertrophy 
or atrophy of skeletal muscle tissue. Hypertrophy is characterized 
by increase in protein synthesis, fiber size and number of 
mitochondria with a consequent enhancement of functionality and 
contractile force of skeletal muscle (Florini et al., 1991; Florini et 
al., 1996; Musarò et al., 1999; Musarò et al., 2001; Musarò et al., 
2004). This condition can be due to an increased functional 
requirement or to hormonal stimulation by factors such as IGF-I 
(Insulin-like Growth Factor I) or utrophin. Muscle specific over-
expression of IGF1 in mice enhanced muscle growth and 
differentiation and maintained muscle mass during ageing (Musarò 
et al., 2001). It was also demonstrated that IGF1 inhibits protein 
degradation and muscle atrophy caused by disuse (Schiaffino et al., 
2013). In skeletal muscle IGF-I activates the phosphatidite-3-kinase 
– Akt/ protein kinase B – mammalian target of rapamycin (PI3K-
Akt/PKB-mTOR) pathway (Bonaldo and Sandri, 2013; Schiaffino 
et al., 2013). mTOR forms two complexes: one with raptor 
(mTORC1) and another with rictor (mTORC2). mTORC1 complex 
promotes protein synthesis in skeletal muscle via S6 kinase 1 
(S6K1) (Le Bacquer . et al., 2007; Schiaffino et al., 2013). S6K1 is 
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necessary to achieve myofiber normal size (Glass, 2005). mTOR  
also controls protein synthesis inhibiting PHAS-1, also known as 
4E-BP (4E-binding protein), a negative regulator of protein 
initiation factor eIF-4E (Glass, 2005). mTOR is also involved in the 
hypertrophic response due to β2-aderenergic agents and androgens 
(Schiaffino et al., 2013). 
PI3K/Akt controls protein balance also regulating FoxO (Forkhead 
box O) transcription factors. FoxO phosphorylation by Akt 
maintains these transcription factors in the cytosol, preventing the 
transcription of the atrophy-related genes, named atrogenes. The up-
regulation of atrogenes, that encode for proteins belonging to the 
ubiquitin-proteasome and autophagy-lysosome systems, leads to 
muscle atrophy (Bonaldo and Sandri, 2013; Schiaffino et al., 2013). 
Skeletal muscle atrophy is defined as a decrease in muscle mass that 
occurs as a result of disuse, starvation, ageing and diseases such as 
diabetes or cancer (Sishi and Engelbrecht, 2011). Atrophy involves 
the shrinkage of myofibers due to protein loss, organelles and 
cytoplasm. In skeletal muscle, atrophy involves several molecular 
pathways. The proteolysis via Ub-proteasome system is mainly 
associated with the increased expression of two E3 ubiquitin ligase 
enzymes: atrogin-1/MAF box and muscle RING finger 1 (MuRF1) 
(Schiaffino et al., 2013). Atrogin-1 promotes MyoD degradation 
and, in myogenic cells, interacts with several proteins, such as 
myosin, desmin, vimentin, enzymes involved in gluconeogenesis 
and glycolysis, mitochondrial proteins and transcription factors. 
MuRF-1 controls the half-life of many structural myo-proteins, such 
as MHC, actin, MLC 1 and 2 and others (Lokireddy et al., 2012; 
Schiaffino et al., 2013). Protein degradation via Ub-proteasome 
required an initial cleavage by activated caspase-3 that correlates 
with the inactivation of PI3K (Kandarian and Jackman, 2006; Wang 
and Rudnicki, 2012). In catabolic conditions of skeletal muscle is 
also involved macroautophagy, another important mechanism of 
protein degradation (Bonaldo and Sandri, 2013; Schiaffino et al., 
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2013). Evidences of FoxO involvement also in macroautophagy are 
given by the correlation between an increased activity of this 
transcription factor and an increased expression of LC3, the key 
protein for the formation of autophagosomal vesicles (Bonaldo and 
Sandri, 2013; Mammucari et al., 2007; Sandri, 2013). Recently 
another transcription factor, JunB, was demonstrated to block 
atrophy and to promote hypertrophy: JunB inhibits atrogin-1 and 
MuRF1, directly binding FoxO3 thus preventing its translocation 
into the nucleus (Bonaldo and Sandri, 2013; Raffaello et al., 2010; 
Schiaffino et al., 2013).  
Furthermore FoxO1 controls myostatin expression. Myostatin is a 
member of TGFβ superfamily and one of the key regulator of 
skeletal muscle mass. It is also demonstrated that myostatin has an 
inhibitory effect on the IGF1-Akt-mTOR pathway via Smad2/3 
(Amirouche et al., 2009; Bonaldo and Sandri, 2013; Sartori et al., 
2009; Trendelenburg et al., 2009). Loss-of-function mutations in 
myostatin gene are known to induce an hypertrophic phenotype in 
mice, sheep, cattle and humans (Bonaldo and Sandri, 2013). 
However the role played by myostatin in inducing muscle atrophy is 
not obvious. The prolonged expression of myostatin leads to muscle 
atrophy due to up-regulation of  ubiquitin ligases (Allen and 
Unterman, 2007; Lee, 2004; Schiaffino et al., 2013; Taylor et al., 
2001) in a FoxO-dependent manner (Bonaldo and Sandri, 2013). 
FoxO activity is modulated by the interaction with many co-factors, 
such as PGC-1α (Peroxisome Proliferator - Activated Receptor 
Gamma Coactivator 1 alpha) a regulator of energy metabolism in 
response to external physiological stimuli, such as cold or 
endurance exercise (Liang and Ward, 2006; Pilegaard et al., 2003). 
PGC-1α inhibits protein degradation down-regulating FoxO3 
activity and NF-κB pathway (Schiaffino et al., 2013). 
The Nuclear-factor-kappa B (NF-kB) transcription factor, is one of 
the most important molecules linked to the loss of skeletal muscle 
mass in a various physio-pathological conditions. Activation of NF-
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kB by pro-inflammatory cytokines, mainly by TNF-α, leads to 
degradation of specific muscle proteins, induces inflammation and 
fibrosis, and blocks the regeneration of myofibers (Li and Reid, 
2000; Schiaffino et al., 2013). Although the activation of NF-kB 
itself requires proteolytic processing of IkB family proteins by the 
ubiquitin-proteasome system (Hayden and Ghosh, 2008; Kumar et 
al., 2004b), NF-kB can induce expression of FoxO transcription 
factors by modulating Akt signalling pathway (Mourkioti et al., 
2006). 
 
 
Figure 2. The balance between protein synthesis and degradation determines 
muscles hypertrophy or atrophy. (Lecker et al., 2006). 
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2.3 Neurohypophyseal hormones as non canonical regulators of 
skeletal muscle homeostasis 
 
Oxytocin (OT) and arginine – vasopressin (AVP), also known as 
antidiuretic hormone, are two small peptides of 9 amino acid 
residues synthesized in magnocellular neurons of the 
paraventricular and supraoptic nuclei of the hypothalamus. They are 
processed along the axonal projections to the neurohypophysis 
where they are stored in secretory vesicles and released into the 
bloodstream in response to a plethora of physiological stimuli 
(Meyer-Lindenberg et al., 2011). 
In women OT is responsible for the ejection of milk during lactation 
and induces contractions during labor. AVP regulates body’s water 
balance predominantly via its modulatory effects on the expression 
and function of the water channel aquaporin-2 and of urea 
transporters in the apical membranes of the epithelial cells of the 
collecting duct of the kidney nephron. AVP is also a vasoconstrictor 
that increases peripheral vascular resistance leading to increased 
arterial blood pressure.  
Interestingly, these neuropeptides play unexpected biological roles 
on many peripheral organs and tissues. Both AVP and OT have a 
relevant role in cardiac homeostasis. AVP induces cardiomyocytes 
hypertrophy and is involved in the pathogenesis of heart failure 
(Hiroyama et al., 2007; Japundzic-Zigon, 2013; Lee et al., 2003). 
Oxytocin actions include water body balance, general down-
regulation of blood pressure and cardiac functions, modulation of 
parasympathetic system, as well as triggered by the NO pathway 
modulating vasodilatation, endothelial cell growth and anti-
inflammatory response (Gutkowska and Jankowski, 2012).  
The role of neurohypophyseal hormones in skeletal muscle 
homeostasis emerged as a novel subject in the last three decades. 
Wakelam et al. had shown the presence of functional AVP receptors 
in the rat myogenic L6 cell (Wakelam et al., 1987). AVP levels 
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were reported to be very high in developing skeletal muscle, and to 
decline during gestation reaching a very low level at birth (Smith et 
al., 1992), suggesting a role for this hormone in muscle 
development. My laboratory characterized the effects of AVP upon 
myogenic cells differentiation both in primary cultured and cell 
lines and analyzed the complex signalling response for such effects 
(Coletti et al., 2000a; Coletti et al., 2000b; Minotti et al., 1998; Naro 
et al., 1997; Naro et al., 1999; Naro et al., 2003b; Naro et al., 2003a; 
Nervi et al., 1995; Scicchitano et al., 2002; Scicchitano et al., 2005; 
Teti et al., 1993). Breton et al. provided evidence that functional 
oxytocin receptors are present in human primary myoblasts (Breton 
et al., 2002; Wakelam et al., 1987). All this observations suggested 
that neurohypophyseal hormones could play a role during skeletal 
myogenesis and contribute to maintain skeletal muscle homeostasis.  
Their specific action on different tissues and organs is due to the 
specific expression of several receptors. Both OT and AVP 
receptors are heptahelical transmembrane proteins activating G 
proteins. The expression of OTR has been characterized in brain, 
uterine myometrium, mammary gland, endometrium, decidua, 
ovary, but also in male reproductive apparatus, thymus, heart and 
kidney (Gimpl and Fahrenholz, 2001), on the surface of vascular 
endothelial cells, osteoblasts, cardiomyocytes and human satellite 
cells (Breton et al., 2002). Three types of receptor are known for 
AVP: V1a, vascular; V1b, corticotrope, V2, renal. V1aR is located 
on both vascular smooth muscle cells and cardiomyocytes, have 
been shown to modulate blood vessel vasoconstriction and 
myocardial function and it is the only isoform expressed in skeletal 
muscle. AVP promotes the phosphorylation and desensitization of 
V1aR. The receptor is internalized in the cytosol, dephosphorylated 
and rapidly returns to the cellular surface (Birnbaumer, 2000; 
Koshimizu et al., 2012). 
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2.4 Arginin-Vasopressin effects on skeletal muscle regeneration  
 
The transduction of AVP signal in myogenic cells involves the 
activation of  phospholipases C and D. AVP induces concentration-
dependent (0.1 nM - 1 µM) stimulation of phospholipase C (PLC) 
activity and regulates the intracellular pH with mechanisms 
involving Na
+
 and anion transport across the plasma membrane. 
Inositol 1,4,5-trisphosphate production was maximally stimulated 
within 2 - 5 sec of treatment with AVP, immediately followed by 
release of Ca
2+
 from intracellular stores. AVP stimulation of 
myogenic cells also results in the activation of phospholipase D 
(PLD) - dependent phosphatidylcholine (PtdCho) breakdown. AVP 
induces the generation of phosphatidic acid (PA) and the increase of 
sn-1,2-diacylglycerol (DAG). AVP treatment of myogenic cells also 
interferes with the cAMP signalling system. It is well known that 
cAMP-dependent protein kinase (PKA) negatively regulates 
myogenic differentiation by inhibiting the activity of myogenic 
Helix-Loop-Helix transcription factors (Li et al., 1992; Winter et al., 
1993). In AVP treated L6 cells selective stimulation of specific 
cAMP-phosphodiesterase isoforms, such as PDE4, in response to 
PA production by PLD was observed (Nemoz et al., 1997). 
Consistently, cAMP levels and PKA activity were down-regulated 
by Vasopressin treatment, allowing the nuclear translocation and the 
transcriptional activity of Myogenesis Regulatory Factors (MRFs) 
(Naro et al., 1999; Naro et al., 2003b).  
The first evidence of biological effects of neurohypophyseal 
hormones as modulators of skeletal muscle differentiation came 
from cell culture experiments. In 1995, Nervi et al. showed that 
supplementing the culture medium of L6 and L5 myoblasts and of 
satellite cells with AVP resulted in an important increase of the 
percentage of fusion and in the formation of hypertrophic myotubes, 
in the absence of significant effects on cell proliferation. The 
expression of early and late myogenic differentiation markers was 
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induced by neurohypophyseal hormones in a structure- and 
concentration- dependent fashion (Nervi et al., 1995). Using a 
serum-free culture medium  for L6 and L5 myoblasts and for mouse 
satellite cells (Minotti et al., 1998) demonstrated that AVP 
effectively induced myogenic differentiation in the absence of other 
factors. Moreover in vitro studies demonstrated that the expression 
of the V1aR receptor is modulated during myogenic differentiation 
(Alvisi et al., 2008), which suggests the physiologic involvement of 
AVP in myogenesis. This hypothesis was also supported by data 
indicating that both in human and murine embryonic and fetal 
muscles high levels of immuno-reactive AVP can be detected 
(Smith et al., 1992). AVP exerts its pro-myogenic effects not only 
on L6 myoblasts but also on primary satellite cells. In these cells 
AVP acts in a dose-dependent manner up-regulating the 
transcriptional levels of Myf5 and myogenin and the expression of 
muscle-specific genes, such as myosin heavy chain (MHC), muscle 
creatine kinase (MCK) and acetylcholine receptors (AChR)  (De 
Arcangelis et al., 2005; Scicchitano et al., 2002).  
Many transcription factors play a crucial role at the nuclear level 
during myogenesis. In addition to Myf5, the MEF2 family 
transcription factors recognize specific DNA elements on the 
promoter of muscle genes. L6 cells treated with AVP showed an 
induction of MEF2A and C during myoblast to myotube transition 
and this induction is concomitant to myogenin expression 
(Scicchitano et al., 2002). The molecular mechanism of this effect 
involves the dissociation of transcriptional repressors class-II 
histone deacetylases (HDACs) from MEF2. Translocation of 
HDACs II from the nucleus to the cytosol allows the transcriptional 
activation of MEF2. The AVP-dependent increase of intracellular 
cytosolic Ca
2+
 concentration activates the CaM-kinase pathway. 
This is sufficient to induce cytosolic compartmentalization of class-
II HDACs, as demonstrated by the reduced nuclear export of the 
HDACs II and MEF2 activation induced by the treatment of L6 
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cells with two CaMK inhibitors (Scicchitano et al., 2002). Moreover 
during AVP-stimulated myogenesis we noted an increase in the 
acetylation levels of histone H3 associated with the myogenin 
promoter and the MCK enhancer. However the AVP-dependent full 
activation of the myogenic program cannot be sustained by CaMK 
alone (Scicchitano et al., 2005). An additional calcium – dependent 
pathway involves Calcineurin A (CnA), a serine/threonine 
phosphatase responsible for the dephosphorylation and the 
consequent nuclear import of NFAT (nuclear factor activating T-
cells) family (Batiuk and Halloran, 1997). Myoblasts treated with 
cyclosporine A (CsA), a partial inhibitor of CnA, or transiently 
transfected with the dominant negative construct CnA - KO showed 
a dramatic down-regulation of myogenic differentiation at both the 
morphological and the molecular level. Moreover CsA treatment of 
L6 cells inhibited the expression of MEF2, NFATc1 and GATA2 (a 
muscle isoform of zinc-finger GATA family), whereas AVP 
administration promoted accumulation of these three transcription 
factors into nuclei (Scicchitano et al., 2005). So AVP stimulates the 
formation of multifactorial complexes including MEF2, NFATc1 
and GATA2 in the myoblast nucleus on the promoter or enhancer 
regions of muscle specific genes via the calcineurin pathway; on the 
other hand the AVP-dependent activation of CaMK promotes 
histone acetylation on the same DNA regions, leading to the full 
expression of the myogenic differentiation program. 
Recent work from our laboratory demonstrated that muscle-specific 
stimulation of AVP signalling induced acceleration of satellite cell 
activation and earlier stimulation of specific pathways involved in 
muscle regeneration. The V1aR over-expression in murine injured 
skeletal muscle was responsible of an anticipation of the 
regeneration program (Toschi et al., 2011). The rapid recovery of 
injured skeletal muscle was associated with a rapid resolution of 
inflammation, earlier activation and fusion of satellite cells, and 
formation of regenerating fibers. The V1aR over-expressing muscle 
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already activated satellite cells and markers of muscle 
differentiation such as Pax7, embryonic MHC, and myogenin, up-
regulated CnA signalling during muscle regeneration and presented 
high expression level of IL-4 (Toschi et al., 2011). 
Taken together these data clearly underline the involvement of the 
AVP-V1aR signalling in skeletal muscle development and 
homeostasis. 
 
 
2.5. A model of skeletal muscle atrophy 
 
Skeletal muscle atrophy is characterized by loss of proteins, 
organelles and cytoplasm with a consequent decrease in muscle 
mass and tissue weakness (Sishi and Engelbrecht, 2011). TNF-α is 
not only a pro-inflammatory cytokine, but this is also a molecule 
usually involved in catabolic conditions of skeletal muscle. As 
demonstrated by Coletti et al. the over-expression of mTNF-α in 
murine skeletal muscle induced muscle atrophy closely similar to 
that observed in cancer cachexia (Coletti et al., 2005). It is known 
TNF-α is able to reduce the number and the size of regenerating 
fibers and to induce the loss of muscle specific protein in a time- 
and concentration-dependent manner (Reid and Li, 2001). 
At a molecular level TNF-α promotes muscle atrophy stimulating 
the Ub-proteasomal system, eg. up-regulating the expression of the 
atrogenes atrogin-1 and MuRF1 (Li et al., 2005). Moreover TNF-α 
activates  JAK/STAT that is sufficient to induce atrophy (Bonetto et 
al., 2012; Schiaffino et al., 2013). TNF-α signalling also involves 
NF-κB activation via TRAF1 and 2 (TNF-α receptor associated 
factors). NF-κB can be a crucial mediator of muscle atrophy, since 
it induces MyoD degradation and cyclin D1 activation which 
promotes cell proliferation, not allowing the myogenic 
differentiation (Coletti et al., 2002; Guttridge et al., 1999). 
Furthermore TNF-α inhibits myogenic differentiation through the 
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activation of caspases in a non-apoptotic pathway (Coletti et al., 
2002; Moresi et al., 2009). However chronic exposure to TNF-α 
also induces apoptosis of myoblasts and myofibers, probably due to 
the activation of caspase-8 (Dirks and Leeuwenburgh, 2006; 
Stewart et al., 2004). 
For all these evidences and in order to study atrophic skeletal 
muscle, we decided to induce a local, acute atrophy over-expressing 
TNF-α by gene delivery by electroporation in murine skeletal 
muscle. 
 
 
2.6. Muscular dystrophies  
 
Lack or impairment of the regenerative capacity of skeletal muscle 
leads to alterations of tissue physiology. Muscular dystrophies are 
an heterogeneous group of genetic disease characterized by 
progressive degeneration of skeletal muscle tissue. Most muscular 
dystrophies are due to defects in trans-membrane protein complexes 
which are fundamental for muscle contraction and sarcolemmal 
integrity. The sarcoglycan complex is a group of single pass 
transmembrane proteins (α-, β-, γ- and δ- sarcoglycan) that is 
associated with sarcospan to form a sub-complex within the 
dystrophin-glycoprotein complex (DGC) in skeletal and cardiac 
muscles. The DGC includes dystrophin and dystroglycan 
complexes, which make contact with cytoskeletal actin and laminin 
in the extracellular matrix respectively (Groh et al., 2009). The 
expression of the sarcoglycan-sarcospan complex is required for the 
stabilization of dystroglycan at the sarcolemma and consequently 
for muscle integrity during contraction. DCG complex plays not 
only a structural role through the sarcolemma, but it is also a key 
regulator in signal transduction. Indeed, DCG interacts with nNOS 
(neuronal nitric oxide synthase) through dystrobrevin and 
syntrophin (Bonaldo and Sandri, 2013; Sandonà and Betto, 2009; 
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Yoshida et al., 2000). Dislocation of nNOS from DCG can increase 
oxidative stress, inflammation and Ub-ligases activity (Lawler, 
2011). DCG also interacts with CaMKII (calmodulin-dependent 
protein kinase II) that phosphorylates several downstream effectors. 
One of its downstream target is the PI3K/Akt pathway that plays a 
crucial role regulating skeletal muscle homeostasis (Bhatnagar and 
Kumar, 2010; Rando, 2001). Many other signalling molecules 
interact with DCG, such as voltage-gated sodium channels and 
phosphatidylinositol 4,5-bisphosphate (Bhatnagar and Kumar, 
2010; Chockalingam et al., 1999; Gee et al., 1998). Moreover Grg2 
(Growth factor receptor-bound protein 2) adaptor protein binds the 
β-dystroglycan leading to the activation of MAPK (Mitogen-
activated protein kinases) signalling cascade. β-dystroglycan also 
directly associates with ERK1/2 (Bhatnagar and Kumar, 2010; Oak 
et al., 2001). 
Mutations within genes in the DGC complex, such as dystrophin, 
leads to Duchenne Muscular Dystrophy (DMD) or Becker muscular 
dystrophy (BMD), while genetic defects of subunits of the 
sarcoglycan complex cause Limb Girdle muscular dystrophies 
(LGMD).  
DMD is caused by an X-linked mutation in dystrophin gene that 
leads to the production of non functional protein (Hoffman et al., 
1987; Watchko et al., 2002). In humans the onset of the disease is 3 
years of age and is characterized by rapid progression which leads 
to early death due to respiratory or cardiac failure (Cox and Kunkel, 
1997; Merrick et al., 2009). The animal model for DMD is the mdx 
mouse that presents a stop codon mutation in exon 23 of the 
dystrophin gene (Hoffman and Schwartz, 1991; Watchko et al., 
2002). Unlike the human progression of the disease, in mdx mice 
skeletal muscle undergoes several cycles of degeneration and 
regeneration of myofibers during 3-5 weeks of life (Pastoret and 
Sebille, 1995; Watchko et al., 2002).  
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Figure 3. The dystrophin – glycoprotein complex. (Sandonà and Betto, 2009) 
 
Inflammation is one of the most important features in muscular 
dystrophies and NF-κB pathway is a key regulator of inflammation 
(Aggarwal, 2004; Bhatnagar and Kumar, 2010; Chen et al., 2005). 
In mdx mice activation of NF-κB and the consequent up-regulation 
of pro-inflammatory cytokines, such as TNF-α and IL-1β, have 
been found before the degeneration peak (Bhatnagar and Kumar, 
2010; Dogra et al., 2006; Kumar and Boriek, 2003). The inhibition 
of NF-κB pathway by both single allele deletion and inhibitory 
peptide reduced inflammatory response and enhanced muscle 
regeneration in mdx mice (Acharyya et al., 2007). Increased NF-κB 
activation has been demonstrated also in DMD patients (Acharyya 
et al., 2007; Bhatnagar and Kumar, 2010; Chen et al., 2005; Monici 
et al., 2003). MAPK pathways, that include ERK1/2 (extracellular 
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signal-related kinase), JNKs (c-Jun N-terminal kinases) and p38-
MAPK, regulate cell proliferation, differentiation, self-renewal and 
survival. Activation of ERK1/2 in pre-necrotic diaphragm 
(Bhatnagar and Kumar, 2010; Kumar et al., 2004a) was 
demonstrated in mdx mice, as well as the activation of JNK1 and 
p38-MAPK (Bhatnagar and Kumar, 2010; Kolodziejczyk et al., 
2001; Nakamura et al., 2001; Nakamura et al., 2002). Another 
important molecular pathway that resulted altered in mdx mice is 
the PI3K/Akt one. Activation of Akt at both pre-necrotic and 
necrotic stages in mdx has been demonstrated (Dogra et al., 2006). 
Mdx mice over-expressing Akt showed enhanced muscle 
regeneration, hypertrophy and decreased sarcolemmal fragility 
(Peter et al., 2009). Moreover Akt stimulates the expression of 
utrophin, that partially compensates the lack of dystrophin (Rafael 
et al., 1998). The Akt-mTOR pathway is also known to modulate 
autophagy. Recently it was demonstrated that the activation of 
autophagy by an AMPK (5' AMP-activated protein kinase) 
antagonist or by stimulating Akt activation ameliorated the 
dystrophic phenotype in mdx mouse model (De Palma C. et al., 
2012). Akt is also implicated in the regulation of intracellular NO 
synthesis (Dimmeler et al., 1999). It was demonstrated that NO is 
involved in epigenetic modifications in other cells (Illi et al., 2008). 
NO deficiency correlating  with increased HDAC5 phosphorylation 
was reported in mdx mice. Phosphorylated HDAC5 is not available 
to associate with HDAC3, an important complex for satellite cells 
activation (Colussi et al., 2009). Moreover mdx mice show 
increased expression of classI HDAC2 and its down-regulation by 
si-RNA was sufficient to induce morphological amelioration of the 
dystrophic phenotype (Colussi et al., 2008). 
Accordingly to the increased calcium influx (Turner et al., 1991) in 
dystrophic muscle and to the interaction of DCG complex with 
CaMK, mdx mice showed an up-regulation in calcineurin-NFAT 
(Nuclear factor of activated T-cell) pathway. Calcineurin 
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dephosphorylates the transcriptional factor NFAT, that enters into 
the nucleus where activates the transcription of muscle specific 
genes (Olson and Williams, 2000; Schulz and Yutzey, 2004), 
inducing skeletal muscle differentiation and hypertrophy. 
Furthermore transgenic mice over-expressing calcineurin showed 
increased levels of utrophin (Bhatnagar and Kumar, 2010; 
Chakkalakal et al., 2003).  
LGMDs are a group of autosomal recessive disorders that 
predominantly affect muscles around the scapular and the pelvic 
girdles. Although the clinical phenotype is very heterogeneous, the 
disease is characterized by loss of ambulation, difficulties in 
breathing and premature death (Sandonà and Betto, 2009). Missense 
mutations in genes encoding β-sarcoglycan give rise to LGMD-2E 
and results in the absence of the other sarcoglycans and in the 
reduction of dystrophin and dystroglycan. Mice presenting a 
substitution of  3-6 exons in Sgc-β gene by neomycin resistance 
gene represent the animal model for human LGMD-2E. Scgβ-null 
mice develop muscular dystrophy with hypertrophic appearance and 
extensive calcification show high levels of serum creatine kinase 
and myocardial fibrosis (Araishi et al., 1999). Scgβ-null mice show 
the first degeneration/regeneration phase in skeletal muscle at 2-3 
weeks of age and another one at 7-9 weeks, while myocardial 
lesions become more evident from 20 weeks of age (Araishi et al., 
1999).  
Little is known about the molecular mechanisms underlying 
LGMD2E and sarcoglycanopathies in general. In δ-sarcoglycan null 
mice the Akt activation levels are higher than in age-matched mdx 
mice (Peter and Crosbie, 2006). In γ-sarcoglycan deficient mice an 
increased apoptosis is accompanied by the activation of ERK1/2 
(Bhatnagar and Kumar, 2010; Griffin et al., 2005). 
Beyond the specific differences within each mouse model, these 
two dystrophic murine models are both characterized by an 
impairment in the contractile mechanism of skeletal muscle. 
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Recurrent myofiber damage elicits a constant need for regeneration. 
In the early phase of the disease the self-renewal potential of 
skeletal muscle is exhausted, the tissue undergoes a progressive 
degeneration and is finally replaced by connective and adipose 
tissue (Meregalli et al., 2013; Sacco et al., 2010).  
Many therapeutic approaches have been proposed for skeletal 
muscle dystrophies, but no one is decisive. Now the most effective 
treatment is based on corticosteroids administration combined with 
physical therapy. Corticosteroids have a well known anti-
inflammatory effect however other mechanisms of action remain 
unclear and their use leads to many side secondary effects (Lopez-
Hernandez et al., 2009; Sandonà and Betto, 2009). Another 
pharmacological treatment, successfully applied in mdx mice, is 
based on amynoglycoside antibiotics that help the stop codon 
readtrhough (Barton et al., 2002; Sandonà and Betto, 2009). 
Another gene-based strategy is the exon skipping in order to 
generate in-frame transcripts, but it is not applicable to 
sarcoglycanopathies because of the absence of dispensable domains 
in sarcoglycans (Sandonà and Betto, 2009). Recently the research is 
focused on cell and gene therapy. The use of adeno-associated viral 
vectors (AAV) is likely to give results in sarcoglycanopathies 
employed before the onset of the disease (Allamand et al., 2000; 
Fougerousse et al., 2007; Sandonà and Betto, 2009). Disadvantages 
of AAV approach are the low distribution of the vector throughout 
the tissue and the small size of exogenous DNA that could be 
inserted (Lopez-Hernandez et al., 2009; Sandonà and Betto, 2009). 
Cell therapy involves grafting of  genetically modified or healthy 
donor cells. Cells can be satellite cells, bone-marrow derived 
mesenchimal stem cells, other muscular stem cells, mesoangioblasts 
and pericytes (Meregalli et al., 2013; Sandonà and Betto, 2009; 
Wilschut et al., 2012). In sarcoglycanopathies the best result was 
obtained with satellite cells transplanted in Scgδ null mice by 
Wallace et al. (Wallace et al., 2008). Injection of mesoangioblasts in 
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which the expression of α-sarcoglycan was rescued by a lentiviral 
vector showed a good potential in Scgα null mice (Sampaolesi et 
al., 2003). Also wild type mesoangioblasts injection in dystrophic 
dogs resulted in an extensive recovery of dystrophin and led to 
general amelioration of the pathology (Sampaolesi et al., 2006). 
Mdx mice treated with mesoangioblasts corrected with a human 
artificial chromosome containing the human dystrophin gene 
showed a morphological and functional amelioration of the 
phenotype for up months after transplantation (Tedesco et al., 
2011). Possible disadvantages of cell therapy are the necessity for 
immunosuppressive treatment and the low diffusion and 
colonization efficiency (Sandonà and Betto, 2009).  
Strategies based on the treatment with IGF-1 or utrophin (an 
homologous protein of dystrophin) aim to compensate muscle mass 
wasting promoting hypertrophy and proliferation/activation of 
satellite cells. The over-expression of IGF-1 in mdx mice led to a 
recovery of the maximum force (Barton et al., 2002), the 
viscoelastic properties of the tendon and the number of alive cells 
(Rizzuto et al., 2013). 
The very recent approach based on the administration of histone 
deacetylase inhibitors (HDACi) to both mdx and Scgα-null mice 
showed an increased cross-sectional area (CSA) of myofibers, 
decreases inflammatory infiltrate and fibrotic tissue formation after 
treatment, unveiling new therapeutic perspective (Consalvi et al., 
2011). 
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3. Aims 
 
The goal of this study is to verify whether the activation of the 
AVP-dependent pathways counteracts muscle wasting in atrophic 
and dystrophic muscles by enhancing anabolic/regenerative 
processes and modulating inflammation. 
With this purpose, by gene delivery electroporation we locally over-
expressed in skeletal muscle of healthy adult mice both the V1a- 
receptor and TNF-α singularly or in combination. 
The strategy of over-expressing the V1aR instead of the 
Vasopressin directly was employed to prevent the well known 
systemic effects of AVP. Otherwise we over-expressed only V1aR 
in dystrophic mice (mdx or Scg-β null mice).  
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4. Results and Discussion 
 
4.1. Validation of the experimental model  
 
Previous data of our group demonstrated that muscle specific over-
expression of the AVP receptor V1a enhanced skeletal muscle 
regeneration after CTX induced damage, by stimulating satellite 
cells activation and increasing the expression of differentiation 
markers (Toschi et al., 2011). TNF is a well known pro-
inflammatory cytokine and it is demonstrated to be sufficient to 
induce muscle atrophy due to cachexia, as well as inhibition of 
muscle regeneration (Moresi et al., 2008). Therefore we decided to 
investigate whether local over-expression of V1aR protects muscle 
from the effects of high levels of TNF. To this purpose we over-
expressed in TA muscles the myosin-light-chain (MLC)-myc-V1a 
AVP receptor construct alone or in combination with the TNF 
construct, by means of gene delivery by electroporation. This 
approach allowed to avoid possible secondary effects of the direct 
AVP administration. Controls of the experimental model were 
mock transfected samples (i.d. muscles transfected with pcDNA3) 
and, when indicated, non-electroporated muscles. In order to assess 
the efficacy of the transfections we preliminary verified, by Real 
Time PCR analysis, the V1aR and TNF transcription levels in 
muscle extracts one week after electroporation (Fig.4A, B). V1aR 
expression is strongly up-regulated in TA muscles electroporated 
with MLC-myc-V1a AVP receptor construct, both in the presence 
and in the absence of TNF, demonstrating that TNF doesn’t 
interfere with the electroporation efficiency or, in general, with the 
forced expression of V1aR (Fig.4A). TNF transcription levels are 
high in samples electroporated with the TNF construct alone or in 
combination with V1aR (Fig.4B).  
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Figure 4. Electroporation efficiency. Real Time-PCR analysis for V1aR (A) 
and TNF (B) expression in TA muscle, one week after electroporation. *p< 0.05; 
** p< 0.01; *** p< 0.001 by Student’s t test. 
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4.2. Local V1aR over-expression in skeletal muscle counteracts 
the negative effects of TNF  
 
Morphological analysis of transfected muscles one week after 
electroporation shows that local over-expression of TNF (Fig.5A, 
panel b and f) caused an accumulation of mono-nucleated 
infiltrating cells.  In addition, high levels of TNF induces myofibers 
damage with a consequent activation of the regenerative process as 
demonstrated by the number of regenerating fibers in this condition. 
While mock-transfected and muscle over-expressing V1aR alone 
didn’t show any alteration of the tissue (Fig.5A, panels a and e, c 
and g, respectively) demonstrating that any damage occurs after 
electroporation.  
As shown in Figure 5B, the number of regenerating muscle fibers 
was the same in muscles over-expressing TNF alone or TNF with 
V1aR. Then the co-transfection of V1aR and TNF didn’t 
significantly affects the number of regenerating fibers (Fig.5B), but 
it affected the fiber size distribution: as shown in Fig.5C, in muscle 
over-expressing both TNF and V1aR we observed a shift in the size 
of  regenerating myofibers towards a wider cross sectional area 
(CSA), 200-400 of square micron, compared to the 100-200 square 
of micron in muscle over-expressing TNF alone. 
These data suggest that TNF over-expression induces damage in 
skeletal muscle, that leads to the activation of the regeneration 
process. However the V1aR over-expression in presence of high 
levels TNF leads to more efficient muscle regeneration as suggested 
by the wider CSA of the myofibers, probably due to an acceleration 
of  the regeneration program.  
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Figure 5. Muscle over-expressing V1aR in atrophic conditions shows 
regenerating fibers with a wider area. (A) H&E stained cross sections of TA of 
control (panels a and e), TNF- (panels b and f), V1aR- (panels c and g), and 
TNF+V1aR- (panels d and h) over-expressing muscles performed one week after 
electroporation. Morphometric analysis of the number of myofiber/CSA divided 
in regenerating, non regenerating and total for all samples (B) and the CSA of the 
regenerating myofibers of TNF- and TNF+ V1aR- transfected muscles (C). *p< 
0.05; ** p< 0.01 by Student’s t test. 
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4.3. Local V1aR modulate inflammatory response and 
fibrogenesis caused by TNF  
 
TNF is a well known pro-inflammatory cytokine capable of 
activating macrophages and of inducing the production of other pro-
inflammatory cytokines, perpetuating the inflammatory response. In 
order to investigate the nature of the mono-nucleated infiltrating 
cells observed in the morphological analysis (Fig. 5A) in muscles 
over-expressing TNF and to verify whether the positive effects of 
V1aR over-expression is associated with a modulation of 
inflammation, we examined by aspecific esterase staining the 
presence of macrophages in our experimental conditions. Fig.6A 
shows a high number of esterase-positive cells in TNF over-
expressing muscles (panel b), whereas the over-expression of V1aR 
significantly attenuated such increase (panel d). While mock-
transfected and V1aR-over expressing muscles were not positive to 
the esterase staining (panels a and c). 
Efficient muscle repair requires the migration and proliferation of 
fibroblasts in order to produce additional extracellular matrix 
(ECM) components, which will act as a scaffold for the new 
myofibers. However, if inflammatory cell infiltration and fibroblast 
activation persist, an aberrant tissue repair response will produce a 
non-functional mass of fibrotic tissue. In order to visualize the 
extent of fibrosis, we performed Masson's trichrome staining in our 
different experimental conditions. Fig.6B showed absence of 
connective tissue in mock muscle (panel a) and in muscles over-
expressing V1aR (panels c and d),  while high levels of TNF were 
related to the formation of fibrosis in skeletal muscle tissue (panel 
b).  
Taken together these data demonstrate that high levels of TNF 
induces an inflammatory response and the formation of fibrotic 
tissue within the muscle, but V1aR over-expression protects 
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muscles against these effects allowing a more efficient regeneration 
process. 
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Figure 6. Muscle over-expressing V1aR counteracts inflammation and 
fibrosis caused by TNF. (A) Aspecific esterase stained TA cross-sections of 
control (panels a), TNF- (panels b), V1aR- (panels c), and TNF+V1aR- (panels d) 
over-expressing muscles performed one week after electroporation highlighted 
the presence of macrophages. B) Masson’s trichrome stained TA cross-sections 
of control (panels a), TNF- (panels b), V1aR- (panels c), and TNF+V1aR- (panels 
d) over-expressing muscles performed one week after electroporation shows the 
presence of fibrotic tissue in muscle. 
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4.4. Modulation of the inflammatory response by V1aR over-
expression involves NF-kB pathway 
 
As previous data demonstrated, muscle over-expressing both V1aR 
and TNF showed less infiltration of mono-nucleated cells and a 
lower esterase activity if compared with muscle over-expressing 
TNF alone. Since these observations indicate that the over-
expression of V1aR down-regulates the inflammation caused by 
TNF expression, we deeper investigated the inflammatory response. 
It is well known that NF-kB pathway  is one of the key regulator of 
the inflammatory system (Smith et al., 1992; Tidball, 2005) and that 
TNF, along with other pro-inflammatory cytokines,  stimulates this 
pathway (Li et al., 1992). As expected, western blot analysis 
(Fig.7A-D) revealed that TNF over-expression promoted a down-
regulation of the NF-kB inhibitory factor IkBα, with a concomitant 
up-regulation in the ratio phosphorylated active NF-kB/total NF-kB. 
Conversely, the phospho-NF-kB/total NF-kB ratio was significantly 
reduced in muscle over-expressing both TNF and V1aR, with a 
concomitant increase of IkBα, demonstrating that V1aR over-
expression attenuated the effects of TNF on inflammation. 
Interestingly V1aR alone seemed to down-regulate phospho-NF-kB 
expression levels with the consequent increase of its inhibitor, 
suggesting a role of AVP-dependant pathways regulating NF-kB 
activation in skeletal muscle  regardless of TNF effects. 
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Figure 7. Modulation of NF-κB pathway in muscle over-expressing V1aR. A) 
Molecular analysis of NF-κB pathway one week after electroporation. Over-
expression of V1aR contributed to a decrease in the expression levels of the 
phosphorylated NF-κB and conversely an increase in the expression of IκB. 
Quantitative analysis in figures B and C. *p< 0.05; ** p< 0.01 by Student’s t test. 
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4.5. Inflammatory cytokine production is modulated by V1aR 
over-expression  
 
To gain further inside into the mechanism by which V1aR 
modulates the resolution of inflammation, we investigated by Real 
Time PCR analysis the expression patterns of specific cytokines and 
chemokines secreted by macrophages with an M1 phenotype, a pro-
inflammatory population capable for perpetuating the inflammatory 
response (Kharraz et al., 2013). Figure 8 demonstrated that the 
expression of CCL2 (8A) chemokine, IL1-β (8B) and IL6 (8C) 
cytokines was strongly up-regulated in the presence of high levels 
of TNF compared to WT, mock- and V1aR-transfected muscles, 
while in the presence of both TNF and V1aR their expression was 
significantly reduced compared to TNF alone (Figures 8A, B and 
C). Interestingly the reduction in such markers for M1 
macrophages, promoted by V1aR over-expression, was associated 
with an up-regulation of relevant markers of the M2 macrophages, 
such as the receptor CD163 and IL-10, IL-4 cytokines (Figures 8D, 
E and F, respectively). These results demonstrated that high levels 
TNF maintains the pro-inflammatory molecules and macrophage 
phenotype, perpetuating the inflammation. While V1aR  over-
expression accelerates the resolution of inflammation caused by 
TNF expression, favoring the shift of macrophages from M1 to M2 
phenotype, stimulating the secretion of anti-inflammatory cytokines 
and thus promoting regeneration process. 
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Figure 8. V1aR over-expression induces the repair phase of inflammation. 
Real Time-PCR analysis for CCL2 (A), IL-1β (B) and IL-6  (C) in wild type, 
mock- , TNF-, V1aR and TNF+V1aR mock transfected muscles one week after 
electroporation. These chemokines and cytokines are typical of the pro-
inflammatory phase and are highly expressed in muscle over-expressing TNF and 
down-regulated by V1aR over-expression (A). On the contrary real Time-PCR 
for CD163 (D) receptor and IL-10 (E) and IL-4 cytokines that characterize the 
resolution phase of inflammation shows an up-regulation in muscles over-
expressing TNF+V1aR. *p< 0.05; ** p< 0.01; *** p< 0.001 by Student’s t test. 
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4.6. The stimulation of AVP-dependent pathways promotes 
skeletal muscle differentiation 
 
The ability of AVP signalling to counteract the negative effects of 
TNF on muscle differentiation was validated in an in vitro cell 
system, the L6 myogenic cells, which are induced to differentiate  
by AVP treatment (Minotti et al., 1998). Of note, TNF treatment 
sustained an undifferentiated phenotype, demonstrated by the 
presence of mono-nucleated myoblasts, by the absence of 
polynucleated myotubes and by the inhibition of MHC and 
myogenin expression. Conversely, AVP counteracted the inhibitory 
effect of TNF and muscle differentiation, up-regulating both 
myogenin and MHC expression and stimulating muscle growth and 
maturation (data not shown). 
Skeletal muscle regeneration consists of a sequence of phenomena 
starting from the activation of satellite cells, followed by their 
differentiation and fusion into myofibers. Therefore we first 
analyzed one week after TNF and/or V1aR electroporation the 
expression of  Pax7, marker of satellite cells, MyoD and desmin, 
early markers of myogenic program activation. Western Blot and 
Real Time PCR analysis demonstrated that TNF over-expression 
greatly increased the expression levels of Pax7 and desmin, 
compared to WT and mock-transfected muscles, whereas MyoD 
expression remained unchanged in all samples. The transfection of 
V1aR alone did not induce significant expression of these proteins. 
In contrast, muscles over-expressing V1aR and TNF showed a 
significant increase in Pax7 and desmin expression (Fig.9 A-C).  
We then analyzed the expression of molecular markers 
characteristic of terminal phase of muscle differentiation, such as 
myogenin and MHC. High levels of TNF down-regulated the 
expression of these markers compared to WT and mock-transfected 
samples, whereas V1aR over-expression enhanced myogenin and 
MHC expression (Fig.9 D and E). Immunofluorescence analysis for 
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another marker of late stage of muscle regeneration, embryonic-
myosin heavy chain (e-MyHC), showed the expression of this 
protein in many small regenerating fibers in muscles over-
expressing TNF and an accumulation in wider regenerating 
myofibers in muscles over-expressing both TNF and V1aR (Fig.9 
F).  
Our hypothesis is that TNF expression stimulates satellite cells 
activation and so muscle regeneration, but fails to complete the 
maturation process. In contrast, the over-expression of V1aR 
counteracts the negative effects of TNF, stimulating muscle growth 
and maturation. 
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Figure 9. V1aR over-expression activates skeletal muscle regeneration even 
in presence of TNF. Molecular analysis one week after electroporation for the 
expression levels of Pax7 (A), MyoD (B) and desmin (C), markers of early 
phases of skeletal muscle regeneration in wild type, mock-, TNF-, V1aR- and 
TNF+V1aR- over-expressing TA muscles. D and E) Molecular analysis one 
week after electroporation for the expression levels of late differentiation markers 
MHC (D) and myogenin (E) in wild type, mock-, TNF-, V1aR- and TNF+V1aR- 
over-expressing TA muscles. F) Immunofluorescence analysis for embryonic 
myosin on TA cross-section of mock- (panel d), TNF- (panel e), V1aR- /panel f) 
and TNF+V1aR- (panel g) over-expressing TA muscles in red. Nuclei were 
counterstained with Hoechst in blue (panels a-d), one week after electroporation. 
*p< 0.05; ** p< 0.01; *** p< 0.001 by Student’s t test. 
38 
 
4.7. Local V1ar over-expression counteracts the effects of TNF 
on protein degradation by stimulating PI3K/Akt signalling  
 
We wondered which molecular mechanisms could be responsible 
for the positive effects of V1aR over-expression on skeletal muscle. 
Since TNF acts on hypertrophy/atrophy balance in skeletal muscle 
inducing protein degradation via ubiquitin-dependent proteasome 
pathway (Li et al., 2005) and since one of the most critical pathway 
involved in regulation of skeletal muscle mass is the PI3K/AKT one 
(Bonaldo and Sandri, 2013; Schiaffino et al., 2013), we investigated 
if V1aR over-expression could modulate this pathway. As shown by 
Western Blot analysis, in presence of high levels of TNF there was 
a decrease of phosphorylated form of Akt, with the consequent 
down-regulation of phospho-FoxO expression levels (Fig.10A.) In 
this condition p-FoxO enters to the nucleus and activates the 
transcription of atrogenes, such as atrogin-1, as shown in Real time 
PCR analysis (Fig.10B). On the contrary V1aR over-expression 
contributed to maintain at a low level the phosphorylation of Akt 
and FoxO (Fig.10A), with a consequent down-regulation of atrogi-1 
transcription (Fig.10B). In agreement with the literature, TNF over-
expression in skeletal muscle stimulated protein degradation, and 
PI3K/Akt pathway is one of the molecular mechanism involved in. 
These results demonstrated that V1aR over-expression stimulates 
PI3K/AKT pathways even in presence of high levels of TNF, 
leading to phosphorylation of FoxO transcription factors at least 
resulting in the inhibition of atrogin-1 expression. 
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Figure 10. V1aR over-expression prevents the TNF-dependent modifications 
of Akt and FoxO. A) Molecular analysis one week after electroporation of Akt 
pathway. In muscles over-expressing TNF the expression of phosphorylated Akt 
and FoxO are down-regulated, whereas V1aR over-expression maintains the 
phosphorylation levels of the same proteins, preventing FoxO to enter into the 
nucleus and to transcript atrogin-1, as shown by the Real-Time PCR in B, 
whereas in presence of TNF atrogin-1 transcription is up-regulated. *p< 0.05; ** 
p< 0.01 by Student’s t test. 
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4.8. Validation of gene delivery electroporation in Scgβ null 
mice  
 
Muscular dystrophies are an heterogeneous group of genetic 
diseases characterized by muscle wasting and progressive loss of 
muscle functionality. Since the results obtained in our model of 
muscular atrophy, we decided to investigate the effects of the 
stimulation of AVP-dependent pathways by local over-expression 
of V1aR by gene delivery electroporation in Scgβ null mice, animal 
model for LGMD (Limb Girdle Muscular Dystrophy). Experiments 
were performed on 8 weeks old mice because it is demonstrated  to 
be the onset of necrosis/regeneration phase of pathology (Araishi et 
al., 1999). Controls of the experimental model were wild type 
(WT), mock transfected (i.d. muscles transfected with pcDNA3) 
and Scgβ null not electroporated muscles. In order to assess the 
efficacy of the transfections, we preliminary analyzed the 
expression of GFP, that was transfected together with V1aR 
plasmid. As Figure 11. shows, all the transfected samples expressed 
GFP positive myofibers (Fig.11 panels b, c, e and f), while GFP 
expression was not detectable in no transfected muscles (Fig.11 
panels a and d), demonstrating the efficiency of the technique in this 
model.  
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Figure 11. GFP positive myofibers after gene delivery by electroporation in 
dystrophic mice. Analysis for GFP positive cells in fresh cryo cross-section of 
TA muscle by wild type (upper panels) and Scgβ null mice (lower panels muscles 
no-electroporated (panels a and d), mock. (panels b and e) and V1aR- (panels c 
and f) transfected samples shows the efficiency of gene-delivery by 
electroporation in this animal model one week after electroporation. 
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4.9. Morphological analysis of the effects of Local V1aR over-
expression in Scgβ null muscle  
 
Morphological analysis one week after electroporation of mutant 
(Scg-β null) transfected muscles shows that mock- transfected 
muscles were subject to extensive damage of myofibers with a 
consequent infiltration of mono-nucleated cells (Fig.12 panels e - f 
and e’- f’), if compared to the untreated mutant muscles that showed 
some necrotic fibers, many regenerating myofibers and less 
extended infiltration of mono-nucleated cells (Fig.12 panels d and 
d’). However in Va1R over-expressing muscles (Fig.12 panels f and 
f’) we noted less infiltrate and regenerating muscle fibers with a 
wider area compared to the mock transfected Scgβ null muscles. All 
the WT samples had unaltered phenotype (Fig.12 panels a- c and a’- 
c’). 
These data suggest that the electroporation caused a damage in Scgβ 
null muscles, probably due to the intrinsic weakness of a dystrophic 
muscle, and that the local V1aR over-expression rescues this 
damage, but its effects on muscular dystrophy are not valuable.   
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Figure 12. Morphological analysis of dystrophic muscles over-expressing 
V1aR. H&E stained TA cross-sections of wild type (upper panels a-c’) and Scgβ 
null mice (lower panels d-f’) of (from left to right) no-electroporated (first 
column), mock- (second column) and V1aR- (third column) transfected muscles, 
one week after electroporation. 
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4.10. Effects of local V1aR over-expression in Scgβ null muscle 
on inflammation and fibrosis 
 
In order to analyze the nature of infiltrating cells observed in mutant 
muscles, we performed the aspecific esterase staining that highlights 
the presence of macrophages. As Fig.13 shows, mock transfected 
mutant muscles appeared highly stained (panels e and e’), V1aR 
over-expressing mutant muscles showed less esterase stained cells 
(panels f and f’) and only few positive cells can be detected in 
mutant untreated muscles (panels d and d’). As expected, all the wt 
samples did not show any macrophage cell (panels a-c and a’-c’).   
These data confirm the hypothesis of muscle damage due to the 
electroporation in mutant muscles. Interestingly local V1aR over-
expression protected skeletal muscle from the inflammation 
consequent to this damage, but we noted no modulation of 
fibrogenesis in these animals. In fact Masson’s trichrome staining 
(Fig.14) shows equal amount of collagen fibers in all mutant 
muscles not electroporated (panels d and d’), mock- (panels e and 
e’) and V1aR-tranfected (panels f and f’). Wt controls didn’t show 
the formation of fibrotic tissue (panels a - c and a’- c’). 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
 
Figure 13. Analysis of inflammation in dystrophic muscles over-expressing 
V1aR. Aspecific esterase staining highlights macrophage activity in TA cross-
sections of wild type (upper panels a-c’) and Scgβ null mice (lower panels d-f’) of 
(from left to right) no-electroporated (first column), mock- (second column) and 
V1aR- (third column) transfected muscles, one week after electroporation. 
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Figure 14. Fibrotic tissue formation in dystrophic muscles over-expressing 
V1aR. Masson’s trichrome staining highlighted the formation of collagen fibers 
in TA cross-sections of wild type (upper panels a-c’) and Scgβ null mice (lower 
panels d-f’) of (from left to right) no-electroporated (first column), mock- (second 
column) and V1aR- (third column) transfected muscles, one week after 
electroporation. 
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4.11. AVP administration ameliorates skeletal muscle 
phenotype in mdx mouse model  
 
We decided to investigate the effects of the stimulation of AVP-
dependent pathways also in 4 weeks old mdx mice, model of 
Duchenne muscular dystrophy. Because of the intrinsic weakness of 
this dystrophic muscles and the early onset of pathology, we cannot 
perform  gene delivery electroporation technique. Thus we analyzed 
muscles after two weeks of treatment with the direct intramuscular 
injection of 25µl of AVP 10-7M (0,1 ng/µl) every 48h. As 
histological analysis shows, we obtained general phenotype 
amelioration both in the TA muscle (Fig.15A panels b and d), that 
was directly treated, and in the Gastrocnemius (Ga) (Fig.15B panels 
b and d) muscle. Contralateral muscles treated with the same 
protocol but with sterile saline solution are used as control and 
showed wider infiltration of mono-nucleated cells and smaller 
regenerating myofibers than the treated muscles (Fig. 15A and B 
panels a and c). 
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Figure 15. AVP administration in dystrophic skeletal muscle ameliorates the 
phenotype. A and B) H&E stained cross sections of untreated (panels a and c) 
and AVP 10
-7 
M treated (panels b and e) animals of TA (A) direct treated muscle 
and Ga (B) muscle after two weeks of treatment. 
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4.12 Discussion 
 
 
Purpose of  this study was to assess if the stimulation of AVP-
dependent pathways could have positive effects in an altered 
homeostatic condition of skeletal muscle: muscular atrophy. Thus 
we induced atrophic stimuli in TA muscles by local over-expression 
of TNF and we analyzed the effects of high levels of AVP receptor 
V1a in this condition. TNF is a pro-inflammatory cytokine and it is 
known to induce murine myoblast apoptosis (Stewart et al., 2004) 
and to block human muscle satellite cell differentiation (Foulstone 
et al., 2004). Moreover, exposure to chronic low levels of 
circulating TNF inhibits muscle regeneration and induce cachexia 
(Coletti et al., 2005). AVP is a neurohypophyseal nonapetide and 
we have demonstrated that it is a potent myogenic promoting factor 
both in vitro and in vivo. AVP acts on skeletal muscle by interacting 
with V1aR. The stimulation of AVP signaling increases cytosolic 
Ca
2+
 concentrations, that activates both calcineurin and CaMK 
pathways which lead to the increased expression of myogenic 
regulatory factors such as Myf5 and myogenin (Nervi et al., 1995; 
Scicchitano et al., 2002; Scicchitano et al., 2005; Teti et al., 1993). 
Accordingly local V1aR over-expression results in acceleration of 
skeletal muscle regeneration after injury (Toschi et al., 2011). 
Furthermore the calcineurin pathway, which is strongly stimulated 
by AVP, was shown to be essential for muscle regeneration in 
normal and dystrophic animals (Stupka et al., 2004). A large body 
of evidence shows that the AVP system is impaired in several 
neuromuscular diseases, such as amyotrophic lateral sclerosis and 
multiple sclerosis (Gonzalez de Aguilar et al., 1999; Michelson et 
al., 1994). Knock-out mouse for V1aR (V1aR -/-) showed 
hyperammonaemia due to an increase of protein catabolism,  
suggesting a role of AVP in the regulation of pathways responsible 
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for the balance between protein synthesis/degradation (Hiroyama et 
al., 2007). 
Morphological analysis clearly demonstrated that the accumulation 
of infiltrating cells in muscle over-expressing TNF alone, 
dramatically decreased when TNF and V1aR are both over-
expressed. Moreover, while V1aR didn’t significantly modify the 
number of regenerating fibers compared with samples over-
expressing TNF alone, it affected the fiber size distribution. The 
increased cross-sectional area of the regenerating myofibers in 
muscle over-expressing V1aR demonstrated a role of AVP in 
accelerating the regeneration process.  
Inflammation is a critical component of muscle physiology and 
represents an important phase in regeneration (Chargè and 
Rudnicki, 2004). In particular, the differential expression of M1 or 
M2 macrophage phenotypes plays a crucial role in the activation of 
satellite cells (Kharraz et al., 2013). Moreover the inflammatory 
process is responsible for the formation of new ECM after damage 
and this assume much importance during the formation of new 
myofiber in skeletal muscle repair (Hogaboam et al., 1998; Wick et 
al., 2013). Here we evaluated whether the enhanced regenerative 
effects observed in V1aR over-expressing muscle correlates with a 
reduction of inflammation and connective tissue accumulation. Our 
results clearly demonstrated that the infiltration of 
monocytes/macrophages and the fibrotic tissue formation observed 
in muscle over-expressing TNF-α were more rapidly resolved in 
presence of high levels of V1aR. An attenuation of the 
inflammatory  response  has been  also evaluated by analyzing the 
effects of the V1aR over-expression on  the activity of  NF-κB. NF-
κB is one of the most important molecular pathways involved in the 
activation and maintenance of the inflammation and it is 
demonstrated to be activated in response to TNF stimuli (Kumar et 
al., 2004b; Sandri, 2008; Schiaffino et al., 2013). The evidence of 
an accelerated resolution of inflammation promoted by V1aR over-
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expression in our model of muscle atrophy is also demonstrated by 
its effect on pro- and anti-inflammatory cytokines expression 
patterns. Local V1aR over-expression selectively down-regulated 
the pro-inflammatory cytokines, such as IL-1β and IL-6 or CCL2 
receptor, whose expression is associated with sustained 
mononuclear cell influx and is usually up-regulated by TNF stimuli 
(Kharraz et al., 2013). Furthermore V1aR over-expression 
correlated with the up-regulation of anti-inflammatory cytokine 
expression, such as CD163, IL-10 and IL-4 which play a major role 
in promoting growth and regeneration of skeletal muscle, at least 
leading to tissue repair (Tidball and Villalta, 2010). Of note the up-
regulation of IL-4, that is not only involved in the regulation of 
inflammatory response, but it is also a molecule able to induce 
myoblasts fusion during skeletal muscle differentiation (Possidonio 
et al., 2011). Being directly correlated with CnA activity, IL-4 is 
synthesized and secreted after the translocation of nuclear factor of 
activated T-cells (NFAT) into the nucleus and stimulates fusion of 
myoblasts to myotubes (Charge and Rudnicki, 2003; Horsley et al., 
2003; Pavlath and Horsley, 2003). Previous studies of our group 
demonstrated that IL-4 was also involved in mediating AVP effects 
on skeletal muscle homeostasis: both in vitro in L6 AVP treated 
cells and in vivo after CTX damage the expression of IL-4 resulted 
up-regulated (Toschi et al., 2011). 
Our data demonstrated that local V1aR over-expression counteracts 
the inflammatory response induced by high levels of TNF and 
enhances the regeneration process after tissue damage caused by 
TNF over-expression. We wondering which molecular mechanism 
could be responsible for the positive effects of V1aR over-
expression on skeletal muscle regeneration. We showed that TNF 
stimulated satellite cells activation and muscle regeneration, as 
demonstrated by the up-regulation of Pax7 and desmin expression, 
but, as expected, impinged the maturation process as showing by 
the low levels of late differentiation markers myogenin and MHC. 
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In contrast, the over-expression of V1aR stimulated muscle 
regeneration and maturation, as demonstrating by  the expression 
levels of the same late differentiation markers. We hypothesized 
that the high levels of TNF compromised the regeneration process 
and V1aR over-expression counteracted this effect. We speculate 
that the positive effects on skeletal muscle regeneration after the 
stimulation of AVP-dependent pathways can be in part due to an 
enhanced fusion process mediated by IL-4 expression via CnA. This 
don’t exclude an involvement of other pathways or of epigenetic 
factors, such as a modulation of class II HDACs, whose localization 
and thus activity is regulated by CaMK, a protein involved in the 
AVP dependent pathways in skeletal muscle.  
TNF is also involved in the activation of catabolic pathways in 
skeletal muscle. One of the most important mechanisms controlling 
protein turnover is mediated by Akt-FoxO. The reduction in the 
activity of the Akt pathway, observed in different models of 
muscular atrophy, results in decreased levels of phosphorylated 
FoxO and consequent up-regulation of atrogenes (Sacheck et al., 
2007; Sandri et al., 2004) which are responsible for the increased 
protein degradation through the ubiquitin-proteasome system 
(Bodine et al., 2001; Gomes et al., 2001; Schiaffino et al., 2013). 
We demonstrated that TNF over-expression up-regulated the 
dephosphorylation of FoxO, thus promoting the transcriptional 
activation of atrogin-1. By contrary, V1aR over-expression 
stimulates PI3K/AKT pathways leading to phosphorylation of FoxO 
transcription factors resulting in the inhibition of atrogin-1 
expression. So the stimulation of AVP-dependent pathways is also 
involved in the positive regulation of protein turn-over in skeletal 
muscle and, in these atrophic conditions, counteracts protein 
degradation activated by high levels of  TNF, maintaining the 
phosphorylation levels of Akt/FoxO pathway, at least down-
regulating atrogin-1 transcription.  
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In this study we demonstrated that the effects of high levels of TNF 
on inflammation, fibrogenesis, regeneration and protein degradation 
in skeletal muscle are strongly counteracted by stimulation of AVP 
signaling. 
Muscular dystrophies are an heterogeneous group of genetic disease 
characterized by a progressive muscle wasting. Guided by the 
results observed in our atrophic model, we extended the study to 
muscular dystrophies, in particular we investigated the effects of the 
stimulation of AVP-dependent pathways in Scgβ null mice, a model 
of LGMD2E, and in mdx mice, a model of DMD. Dystrophic 
muscle show many similarities with atrophic muscle. As in our 
model of muscular atrophy, also in muscular dystrophies 
inflammation is an important process, even if here the scenario is 
dominated by a chronic inflammatory response, mainly due to T 
cells, that exacerbates muscle wasting (Porter et al., 2002). It was 
demonstrated that high levels of TNF in muscular dystrophies 
activate NF-κB pathway, that induces Ub-proteasome system 
(Charan et al., 2012; Li and Lin, 2008; Mourkioti and Rosenthal, 
2008) up-regulating Murf1 and atrogin-1 (Charan et al., 2012; 
Kandarian and Jackman, 2006; Schiaffino et al., 2013) and down-
regulating MyoD expression (Charan et al., 2012; Guttridge et al., 
2000). While high levels of TNF in our atrophic model are 
responsible for the activation of muscle catabolism via Akt-FoxO, 
in mdx mice PI3K/Akt pathway was demonstrate to be up-
regulated,  probably for compensating the loss of myofibers, in 
particular phosphorylated Akt activates mTor that promotes protein 
synthesis (Peter and Crosbie, 2006).  
In our studies on Scgβ null mice we decided to over-express V1aR 
by gene delivery electroporation in 8 weeks old mice because at this 
stage muscles are subject to the pick of degeneration (Araishi et al., 
1999). V1aR over-expressing mutant muscles showed a general 
amelioration of muscle conditions if compared to mock-transfected 
muscle, but not compared to a no-transfected mutant muscle. Thus 
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the electroporation in this mice induced a damage probably due to 
the intrinsic weakness of the dystrophic muscles. In our opinion 
further studies will require less invasive techniques to vehicle the 
trans-gene in dystrophic muscles. Since in mdx mice gene delivery 
by electroporation caused too huge damage to muscle tissue at 3 
weeks of age, when there is the first cycle of 
degeneration/regeneration (Pastoret and Sebille, 1995; Watchko et 
al., 2002), we decided to administrate AVP 10-7M by intramuscular 
injection. We noted an amelioration of the dystrophic phenotype 
already at one week of treatment (data not shown); such 
amelioration is more evident after two weeks. Both the directly 
treated (TA) and the adjacent muscle (Ga) showed less necrotic 
fibers, regenerating fibers with a wider CSA and less infiltration of 
mono-nucleated cells. These data suggest that AVP could exert its 
positive effects even in the adjacent muscles and not only on the 
injected muscle. It is not clear whether this effect depends on local 
or systemic distribution of AVP.  
Concluding this study demonstrated that the over-expression of 
TNF-α in skeletal muscle by gene delivery electroporation is 
responsible for the stimulation of inflammatory response, 
demonstrated by the increased number of macrophages; at a 
molecular level stimulates the activation of NF-κB and the 
expression of pro-inflammatory molecules typical of the M1 
macrophage phenotype. High levels of  TNF-α down-regulate the 
phosphorylation of Akt and FoxO inducing atrogin-1 transcription, 
leading at least to the activation of muscle catabolism. TNF-induced 
damage of myofibers activates the regeneration process stimulating 
satellite cells, however the regeneration doesn’t progress beyond the 
early stages. The stimulation of AVP-dependent pathways by local 
V1a receptor over-expression significantly counteracts the negative 
effects of TNF on skeletal muscle. In fact high levels of V1aR in 
presence of TNF in skeletal muscle inhibited the inflammatory 
response down-regulating the p-NF-κB and promoting the 
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expression of cytokines and chemokines typical of M2 macrophagic 
phenotype and of the resolution of inflammation. V1aR over-
expression counteracts TNF-induced effects on skeletal muscle 
regeneration promoting the progression of differentiation until the 
late stage of the process. Finally AVP-dependant pathways are also 
able to regulate muscle metabolism maintaining the 
phosphorylation levels of the proteins involved in PI3K/Akt/FoxO 
pathway. Moreover in dystrophic skeletal muscle the stimulation of 
AVP-dependent pathways exerts positive effects on degenerating 
muscles, probably enhancing regeneration of myofibers and 
attenuating inflammatory response. 
Our study highlights the positive role of the stimulation of AVP-
dependant pathways in atrophic and dystrophic muscle at a 
morphological and molecular level. Our data can provide a baseline 
for the future development of strategies to improve muscle 
regeneration in myopathies. 
 
 
5. Materials and methods 
 
5.1 Cell culture 
 
L6 rat myogenic cells were seeded 12.000/cm2 and cultured in 
DMEM (Sigma-Aldrich, St. Louis, MO) supplemented with 20 mM 
Hepes pH 7.4, 50 µg/ml gentamicin solution (Sigma-Aldrich),  2 
mM L-glutammine and 10% heat-inactivated FBS (Sigma-Aldrich). 
Twenty-four hours after plating cultures were shifted to DMEM 
supplemented with 1% fatty free BSA (Sigma-Aldrich) and treated 
with 10-7M of synthetic AVP (Sigma-Aldrich) or 5 ng/ml of 
mTNF-α (Roche, Molecular Biochemicals, Mannheim, Germany) 
or both of them, for the latter treatment TNF was added 30 minutes 
after the treatment with AVP.  
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5.2 Animals 
 
C57 transgenic desmin/nls-lacZ mice used in this study bear the 1 
kb DNA 5’ regulatory sequence of the desmin gene linked to a 
reporter gene coding for Escherichia coli-β-galactosidase 
(Lescaudron et al., 1993). The desmin-lacZ transgene labels muscle 
cells in which the desmin synthesis program has commenced 
(Lescaudron et al., 1997). Where indicated C57BL/10ScSn-
Dmdmdx/J (mdx mice) and B6.129-Scgbtm1Kcam/2J (Scg-beta 
null mice) mice were also used as models of Duchenne muscular 
dystrophy and Limb Girdle Muscular Dystrophy (LGMD), 
respectively. Mice were treated according to the guidelines of the 
Institutional Animal Care and Use Committee. Animals were 
anesthetized with an intraperitoneal injection of Avertin A (2,2,2-
tribromoethanol and 2-methilbutanol from Sigma Aldrich) before 
gene delivery by electroporation. After 7 days mice were sacrificed.  
 
 
5.3 Plasmid construction 
 
MLC-Myc-V1aR plasmid used in this work was derived from 
MLC-Myc and PCD3-V1aR (kindly provided by Prof. S.J. Lolait, 
Univ. of Bristol, UK) expression vectors, as previously described by 
Toschi (Toschi et al., 2011). To induce expression of the secreted 
form of murine TNF-α, we used the construct pBabe-mTNF-α 
(kindly provided by Dr. Gokhan Hotamisligil, Harvard University, 
Boston, MA) under control of the SV40 promoter. The SV40 
promoter has been demonstrated to be efficient for driving 
exogenous cDNA expression in skeletal muscle (Lupa-Kimball and 
Esser, 1998). As transfection control was used SNAP25-GFP 
plasmid.  
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5.4 Gene delivery by electroporation 
 
The Tibialis Anterior (TA) was injected with the indicated amount 
of cDNA: 20 µg of MLC-Myc-V1aR, PCDNA3 (Toschi et al., 
2011), pBabe-mTNF-α or 10 µg of MLC-Myc-V1aR with 10 µg of 
pBabe-mTNF-α, in combination with 5 µg of pCMV-SNAP-GFP 
(kindly provided by Dr. Pozzan, Univ. of Padua, Italy), as a marker 
of transfection efficiency. The electric pulses were delivered using 
3X5 mm Gene Paddles electrodes (BTX, San Diego, CA) placed on 
either side of the muscle, as described by Donà (Donà et al., 2003). 
This protocol of gene delivery by electroporation guarantees a 
stable DNA expression for more than four months. 
 
 
5.5 Histological and histochemical analysis 
 
TA muscles transfected with MLV-Myc-V1aR, PCDNA3 or pBabe-
mTNF-α were dissected from 7 weeks old desmin-lacZ mice, 
embedded in Jung tissue freezing medium (Leica, Wetzlar, 
Germany) and frozen in liquid nitrogen-cooled isopentane. 
Cryosections of 7 µm were obtained using a Leica cryostat. 
Sections were observed under the green activation filter of 
Axioskop 2 plus system (Zeiss). For histological analysis, sections 
were stained with hematoxylin and eosin (H&E) using standard 
methods. Alternatively cryosections were treated for Masson’s 
trichrome staining according to Sigma Aldrich kit protocol. 
Esterase staining was adapted from Davis (DAVIS, 1959) as 
previously reported (Berardi et al., 2008). Cryosections of each 
muscle were incubated for 5 min in a staining solution containing: 3 
mg alpha-naphthyl acetate, 0.375 ml acetone, 6.25 ml 0.2 M sodium 
phosphate and 0.4 ml of a solution containing equal volumes of 2% 
pararosaniline (Sigma-Aldrich) and 2% sodium nitrite. 
Photomicrographs were obtained using an Axioscop2 plus system 
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equipped with an Axiocam HRc (Zeiss, Oberkochen, Germany) at 
1300x1030 pixel resolution and analyzed using 10x NA 0.30 air 
objective lens or 20x NA 0.50 air objective lens.  
 
 
5.6 Morphometric and statistical analysis  
 
Photomicrographs of the regenerating muscle fibers (identified by 
morphological criteria, i.e. centrally located nuclei in H&E stained 
sections) were taken at standard resolution (1.300x1030 pixel) and 
analyzed using ImageJ, Scion Image software. For the 
morphometric evaluation of fiber size we analyzed the overall 
number of regenerating muscle fibers/ TA cross section and we the 
size of 200 regenerating muscle fibers of the muscles over-
expressing pBabe-mTNF-α alone or pBabe-mTNF-α and MLC-
Myc-V1aR. All data are expressed as mean ± SD. Statistical 
analysis was performed by means of Student’s t test.  
 
 
5.7 Immunofluorescence analysis 
 
Transverse TA muscle cryosections were fixed in 4% 
paraformaldheyde for 10 min on ice and washed with PBS. After 
incubation in 1% BSA (Sigma-Aldrich) for 30 min at RT, 
cryosections were incubated over night at 4 °C with embryonic 
myosin (F1.652) from Developmental Hybridoma-bank and then for 
1h at RT with the appropriate secondary antibody, Alexa fluor 568-
conjucated anti-mouse (Molecular Probes, Eugene, OR, USA) 
1:500 in 1% BSA. Nuclei were stained with 0.5 ug/ml Hoechst 
33342 (Sigma-Aldrich). The sections were mounted with 
Vectashield mounting medium (Vector Laboratories, Burlingame, 
CA) and examined with an Axioskop 2 plus system (Zeiss) or a 
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Leica Leitz DMRB microscope fitted with a DFC300FX camera for 
confocal analysis (Leica). 
 
 
5.8 Gene expression analysis 
 
TA muscles were dissected, minced and homogenized. Total RNA 
was extracted by means of Trizol Reagent (Invitrogen, Carlsbad, 
CA) following the manufacturer’s protocol. RT-PCR was 
performed using 1 µg of total RNA that was reverse-transcribed 
using Moloney Murine Leukemia Virus Reverse Transcriptase (M-
MLV RT; Invitrogen, Carlsbad, CA).  
For Real-time PCR, cDNA was performed from three independent 
RNA preparation, while quantitative PCR was performed with ABI 
Prism 7500 PCR instruments (Applied Biosystems) using the 
TaqMan gene expression assay to amplify samples in triplicate for 
TNF (Mm00443258-m1) V1aR (assayMm00444092_m1), CCL2 
(Mm00441242-m1), IL1-beta (Mm01336189-m1), IL6 
(Mm0120733-m1), Cd163 (Mm004744096-m1), IL10 
(Mm00439616-m1), IL-4 (Mm00445260-m1) Pax7 
(Mm00834082_m1), Desmin (Mm00802455-m1) and Myogenin 
(Mm00446194-m1), Atrogin-1 (Mm01207878_m1) and GAPDH 
(Mm00656735-m1) or HPRT (Mm00446968_m1) as internal 
control. 
  
 
5.9 Immunoblotting analysis 
 
TA muscle were dissected, minced and homogenized with RIPA 
buffer (20 mM Tris/HCl pH 7.5, 2mM EDTA, 2mM EGTA, 0.25M 
Sucrose, 5mM DTT, 0,1% Triton X-100, 10mM NaF, 200 µM 
sodium orthovanadate) and sonicated. Equal amount of proteins (20 
µg for cells and 30 µg for muscles), determined by BCA protocol, 
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were separated by SDS PAGE and transferred electrophoretically to 
Hybond-C Extra nitrocellulose membrane (Amersham Biosciences, 
Piscataway, NJ). Aspecific binding sites were blocked in TBST 5% 
non-fat milk for 1h. Then the membrane was incubated over night 
with the monoclonal primary antibodies in 5% BSA/TBST: anti-IL-
4 2 μg/ml (R&D system), anti-Pax7 from Developmental 
Hybridoma-bank undiluted, anti-MyoD (Santa Cruz 
Biotechnologies) 1:500, anti-MHC (MF20) from Developmental 
Hybridoma-bank, anti-myogenin F5D from Developmental 
Hybridoma-bank undiluted, anti-α-tubulin (Sigma-Aldrich) 1:50, 
anti-GAPDH (Santa Cruz Biotechnologies) 1:10000, or with the 
polyclonal primary antibodies anti-NFkB (C22B4) and anti-
phospho NFkB p65 (Ser563) (93H1), diluted 1:1000 (Cell 
Signaling), anti-calcineurin Pan A (Chemicon International) 1:500, 
anti-phospho Akt (Ser473), anti-FoxO3a (75D8), anti-phospho 
FoxO3a (Ser253) diluted 1:1000. Blots were washed in TBST and 
then incubated with the appropriated secondary antibody, goat anti-
mouse or anti-rabbit HRP-conjugated (Bio-Rad Laboratories, 
Hercules, CA) in TBST containing 1% non-fat milk. Blots were 
extensively washed and the antibody binding was detected by Super 
Signal West Pico Chemiluminescent Substrate (Pierce, Rockford, 
IL). 
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